Breast Cancer Drugs Market - Global Industry Analysis

Breast Cancer Drugs Market by Drug Type (Hormone Therapy, Chemotherapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 15-Mar-2019 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-70 Status : Published

Global breast cancer drugs market expected to generate around USD 38.3 billion by 2025, at a CAGR of around 10.55% between 2019 and 2025. The increasing breast cancer prevalence worldwide is the major driving factor for the global breast cancer drugs market along with increasing health awareness, healthcare spending, and rising disposable income of people.

Description

The report covers a forecast and an analysis for the breast cancer drugs market on a global and regional level. The study provides historical data from 2016 to 2018 along with forecast from 2019 to 2025 based on revenue (USD Billion). The study includes drivers and restraints for the breast cancer drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the breast cancer drugs market on a global and regional level.

In order to give the users of this report a comprehensive view of the breast cancer drugs market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Global Breast Cancer Drugs Market

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the breast cancer drugs market by segmenting the market based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs.

Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies. Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc. The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Some key players of the global breast cancer drugs market include AbbVie, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Biocon, Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc.

This report segments the global breast cancer drugs market into:

Global Breast Cancer Drugs Market: By Drug Type

  • Chemotherapy Drugs
    • Anthracyclines
      • Doxorubicin
      • Epirubicin
    • Taxanes
      • Paclitaxel
      • Docetaxel
    • Antimetabolites
      • Fluorouracil
      • Capecitabine
      • Gemcitabine
    • Alkylating Agents 
    • Epothilones
  • Hormone Therapy Drugs
    • Selective Estrogen-Receptor Modulators (SERMs)
      • Tamoxifen
      • Raloxifene
      • Toremifene
    • Aromatase Inhibitors
      • Letrozole
      • Anastrozole
      • Megestrol
    • Other Hormonal Therapies
      • Goserelin acetate
      • Fulvestrant
      • Fluoxymesterone
  • Targeted Therapy Drugs
    • Monoclonal Antibodies (mAbs)
      • Bevacizumab
      • Trastuzumab
      • Other mAbs
    • Tyrosine kinase inhibitors
  • Other Therapeutic Drugs

Global Breast Cancer Drugs Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Breast Cancer Drugs Market Revenue, 2016-2025 (USD Billion)
    • 2.2. Global Breast Cancer Drugs Market: Snapshot
  •  
  • Chapter 3. Breast Cancer Drugs Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Breast Cancer Drugs market drivers: Impact analysis
      • 3.2.2. Increasing Prevalence of Breast Cancer
      • 3.2.3. Patent Expiry
    • 3.3. Market Restraints
      • 3.3.1. High Cost of Treatment
    • 3.4. Opportunities
      • 3.4.1. Increasing research and development of novel therapies
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Drug Type
      • 3.6.2. Market attractiveness analysis, by Region
  •  
  • Chapter 4. Global Breast Cancer Drugs Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Breast Cancer Drugs Market: Company Market Share, 2018
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development and Regional Expansion
  •  
  • Chapter 5. Global Breast Cancer Drugs Market - Drug Type Analysis
    • 5.1. Global Breast Cancer Drugs Market: DrugTypeoverview
      • 5.1.1. Global Breast Cancer Drugs Market revenue share, by Drug Type, 2018 and 2025
    • 5.2. Chemotherapy Drugs
      • 5.2.1. Global Breast Cancer Drugs Market for Chemotherapy Drugs, 2016-2025 (USD Billion)
    • 5.3. Hormone Therapy Drugs
      • 5.3.1. Global Breast Cancer Drugs Market for Hormone Therapy Drugs, 2016-2025 (USD Billion)
    • 5.4. Targeted Therapy Drugs
      • 5.4.1. Global Breast Cancer Drugs Market for Targeted Therapy Drugs, 2016-2025 (USD Billion)
    • 5.5. Other Therapeutic Drugs
      • 5.5.1. Global Breast Cancer Drugs Market Other Therapeutic Drugs, 2016-2025 (USD Billion)
  •  
  • Chapter 6. Global Breast Cancer Drugs Market - Regional Analysis
    • 6.1. Global Breast Cancer Drugs Market: Regional overview
      • 6.1.1. Global Breast Cancer Drugs Market revenue share, by region, 2018 and 2025
    • 6.2. North America
      • 6.2.1. North America Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.2.2. The U.S.
        • 6.2.2.1. The U.S. Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.2.3. Rest of North America
        • 6.2.3.1. Rest of North America Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
    • 6.3. Europe
      • 6.3.1. Europe Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.3.2. Germany
        • 6.3.2.1. Germany Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.3.3. U.K.
        • 6.3.3.1. U.K.Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.3.4. France
        • 6.3.4.1. France Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.3.5. Rest of Europe
        • 6.3.5.1. Rest of Europe Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
    • 6.4. Asia Pacific
      • 6.4.1. Asia PacificBreast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.4.2. China
        • 6.4.2.1. China Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.4.3. Japan
        • 6.4.3.1. Japan Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.4.4. India
        • 6.4.4.1. India Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.4.5. Rest of Asia Pacific
        • 6.4.5.1. Rest of Asia Pacific Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
    • 6.5. Latin America
      • 6.5.1. Latin America Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.5.2. Brazil
        • 6.5.2.1. Brazil Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
      • 6.5.3. Rest of Latin America
        • 6.5.3.1. Rest of Latin America Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)
  •  
  • Chapter 7. Company Profile
    • 7.1. F. Hoffmann-La Roche Ltd.
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business strategy
      • 7.1.5. Recent developments
    • 7.2. Novartis AG
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business strategy
      • 7.2.5. Recent developments
    • 7.3. AbbVie, Inc.
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business strategy
      • 7.3.5. Recent developments
    • 7.4. AstraZeneca
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business strategy
      • 7.4.5. Recent developments
    • 7.5. Eli Lilly and Company
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business strategy
      • 7.5.5. Recent developments
    • 7.6. Celgene Corporation
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business strategy
      • 7.6.5. Recent developments
    • 7.7. Biocon
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business strategy
      • 7.7.5. Recent developments
    • 7.8. Merck & Co., Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business strategy
      • 7.8.5. Recent developments
    • 7.9. Genzyme Corporation
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business strategy
      • 7.9.5. Recent developments
    • 7.10. Janssen Global Services LLC
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business strategy
      • 7.10.5. Recent developments
    • 7.11. MacroGenics, Inc.
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfolio
      • 7.11.4. Business strategy
      • 7.11.5. Recent developments
    • 7.12. Celldex Therapeutics
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfolio
      • 7.12.4. Business strategy
      • 7.12.5. Recent developments
    • 7.13. Onyx Pharmaceuticals Inc.
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfolio
      • 7.13.4. Business strategy
      • 7.13.5. Recent developments
    • 7.14. BioNumerik Pharmaceuticals, Inc.
      • 7.14.1. Overview
      • 7.14.2. Financials
      • 7.14.3. Product Portfolio
      • 7.14.4. Business strategy
      • 7.14.5. Recent developments

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Breast Cancer Drugs Market revenue, 2016–2025 (USD Billion)
4. Porter’s Five Forces Analysis
5. Breast Cancer Drugs Market attractiveness analysis, by Drug Type
6. Breast Cancer Drugs Market attractiveness analysis, by Region
7. Company market share analysis, 2018
8. Global Breast Cancer Drugs Market revenue share by Drug Type, 2018 and 2025
9. Global Breast Cancer Drugs Market Revenue for Chemotherapy Drugs, 2016–2025 (USD Billion)
10. Global Breast Cancer Drugs Market Revenue for Hormone Therapy Drugs, 2016–2025 (USD Billion)
11. Global Breast Cancer Drugs Market Revenue for Targeted Therapy Drugs, 2016–2025 (USD Billion) 
12. Global Breast Cancer Drugs Market Revenue for Other Therapeutic Drugs, 2016–2025 (USD Billion) 
13. North America Breast Cancer Drugs Market Revenue, 2016–2025 (USD Billion)
14. Europe Breast Cancer Drugs Market Revenue, 2016–2025 (USD Billion)
15. Asia Pacific Breast Cancer Drugs Market Revenue, 2016–2025 (USD Billion)
16. Latin America Breast Cancer Drugs Market Revenue, 2016–2025 (USD Billion)
17. The Middle East and Africa Breast Cancer Drugs Market Revenue, 2016–2025 (USD Billion)


Table Of Tables

List of Tables

1. Breast Cancer Drugs Market: Market Snapshot
2. Drivers of global Breast Cancer Drugs Market: Impact analysis 
3. Restraints of Global Breast Cancer Drugs Market: Impact analysis  
4. North America Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
5. The U.S. Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
6. Rest of North America Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
7. Europe Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
8. Germany Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
9. UK Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
10. France Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
11. Rest of Europe Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
12. Asia Pacific Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
13. China Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
14. Japan Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
15. India Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
16. Rest of Asia Pacific Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
17. Latin America Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
18. Brazil Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
19. Rest of Latin America Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)
20. The Middle East and Africa Breast Cancer Drugs Market Revenue, by Drug Type, 2016–2025 (USD Billion)

Methodology

Free Analysis

Breast cancer is an uncontrolled growth of breast cells typically lobules or ducts of the breast. Cancer is caused due to mutations in the gene regulator sequence. Cancer can occur in the fibrous connective tissues or fatty tissues within the breasts. Breast cancer mainly is categorized into—invasive and noninvasive. Breast cancer is among the most common types of cancers occurring in women and is the second most common cancer type. As per the Globocon 2018, there are more than 2.08 million new cases of breast cancer worldwide, i.e., about 11.6% of all types of cancers.

The increasing breast cancer prevalence worldwide is the major driving factor for the global breast cancer drugs market along with increasing health awareness, healthcare spending, and rising disposable income of people. Investments made by major market players for novel drug development and favorable reimbursement policies are also contributing to the breast cancer drugs market globally. Additionally, government funding/grants for research and development and patent expiry will further propel this market’s growth in the future. However, the high cost of treatment may hamper the breast cancer drugs market growth.

Global Breast Cancer Drugs Market

The global breast cancer drugs market segments are based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs. Chemotherapy drugs held the largest market share in 2018, whereas targeted therapy drugs are expected to show the highest CAGR over the forecast time period. Targeted therapy helps the immune system destroy cancer cells by interfering with specific proteins and fights the cancer cells only along with having lesser side effects as compared to chemotherapeutic drugs. This will fuel the targeted therapy drugs’ market popularity over the estimated timeframe. Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies. Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc. The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs.

By region, North America dominated the global breast cancer drugs market with a market share of about 43% in 2018 and is projected to retain its leading position over the forecast time period as well. This can be attributed to the increasing prevalence of breast cancer, growing health awareness, the presence of key market players in the region, ongoing drug discovery research and development projects, favorable reimbursement policies for breast cancer, increasing use of breast cancer targeted therapies as precision medicine, and presence of developed healthcare infrastructure. Europe held the second largest market share in 2018 of the global breast cancer drugs market, owing to the growing adoption of targeted therapies, increasing breast cancer prevalence, favorable reimbursement policies, and developed healthcare infrastructure. Asia Pacific is projected to witness the highest CAGR over the forecast time period in the global breast cancer drugs market, due to the growing health awareness, increasing disposable income, and rising healthcare spending, increasing breast cancer burden.

Some key players of the global breast cancer drugs market include AbbVie, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Merck & Co., Inc., Biocon, Genzyme Corporation, MacroGenics, Inc., Janssen Global Services LLC, Onyx Pharmaceuticals Inc., Celldex Therapeutics, and BioNumerik Pharmaceuticals, Inc.

Choose License Type

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • paypal
  • amazon
  • visa
  • master card

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed